Sun Pharma arrangements to procure a marked oncology item Odomzo from Novartis for a forthright installment of USD 175 million and extra development installments, said the organization in its public statement to BSE. The item would bolster their venture into marked oncology with an eye on worldwide markets. "Odomzo gives us a chance to seriously extend our effectively settled marked dermatology business and bolster our venture into Branded Oncology with a propelled mark. We see important worldwide potential for Odomzo by utilizing Sun Pharma's current dermatology and oncology framework to give an inventive item to BCC patients around the world.
For more information Call us ✆ +91 7400-734000 or Visit
Dollar Advisory
No comments:
Post a Comment